Welcome to Merz

News

• 08. April 2013

  Merz Pharma Group Withdraws Proposal to Acquire Obagi Medical Products

  Merz Pharma Group (“Merz” or “the Company”) today announced that it has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products, Inc. (NASDAQ-GS: OMPI) (“Obagi”) for $22 per share in cash. The decision to withdraw the proposal follows the recent announcement that Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) increased its offer to acquire Obagi from $19.75 to $24.00 per share in cash, pursuant to an amendment to the Valeant and Obagi Agreement and Plan of Merger, dated March 19, 2013.

• 02. April 2013

  Merz Pharma Group Makes Superior Proposal to Acquire Obagi Medical Products

  In a letter to the Board of Directors of Obagi Medical Products, Inc. (NASDAQ-GS: OMPI) (“Obagi”), Merz Pharma Group (“Merz” or “the Company”) today outlined a proposal to acquire all of the outstanding common stock of Obagi for $22 per share in cash. This proposal represents a 58% premium to Obagi’s closing share price on Thursday, March 14, 2013, the last trading day prior to the disclosure on Obagi’s fourth quarter earnings call that Obagi had engaged a financial advisor to help explore “all opportunities.”

• 30. November 2012

  Merz Pharma Group growing significantly faster than the market

  The Merz Pharma Group saw significant double-digit growth in the reporting period, with Group revenue up 17.0 % to EUR 913.1 million. At EUR 263.5 million, earnings before interest and taxes (EBIT) reached a new record despite the fact that expenditure on research and development remained high.

• 17. October 2012

  Professor Marjan van den Akker named 22nd Friedrich Merz Guest Professor/Prestigious symposium on the topic of multimorbidity

  Professor Marjan van den Akker of Maastricht University was named this year’s Friedrich Merz Guest Professor for Pharmacy and Human Medicine at Goethe University Frankfurt.

• 07. September 2012

  Pierre Fabre and Merz Sign Aesthetic Dermatology Agreement - Merz Takes Over Injectable Glytone® Products

  Castres/ Frankfurt, September 6, 2012  In accordance with the announcement made on May 9th, pharmaceuticals laboratories Pierre Fabre (France) and Merz Pharmaceuticals (Germany) have signed a partnership agreement on the marketing of Glytone® products. Under this agreement, Merz Group acquires the Glytone® range of injectable hyaluronic acid products used to fill wrinkles, as well as several accompanying dermo-cosmetic products. Merz becomes owner of the global rights to Glytone® injectable hyaluronic acid products and the non-US rights to the other products of the brand.

• 26. June 2012

  Generational succession among the shareholder families of Merz / change in the operative management at Merz KGaA

  The management of Merz KGaA is going to change. The long-planned generational succession in the shareholder families takes effect on July 1, 2012.

• 09. May 2012

  Pierre Fabre and Merz in exclusive negotiations to collaborate in Aesthetics – Merz planning to take on Glytone® filler range

  Pierre Fabre (France) and Merz Pharmaceuticals (Germany) today announced the kick-off of exclusive negotiations to collaborate in aesthetics. Initially, Merz intends to acquire Glytone’s® fillers, a unique family of hyaluronic acid injectables to reduce wrinkles and their accompanying dermo-cosmetic products.

• 26. January 2012

  Change of Management at the Merz Pharma Group

  A change in the Management Board of the Merz Pharma Group is taking place. Dr. Martin Zügel, Chairman of the Board, will leave the company in the course of the year to pursue other interests.

• 23. November 2011

  Merz Pharma Group continues to flourish

  Strong growth in group revenue (20.1%) and EBIT (10.6%) with research and development expenses remaining constant / Memantine builds on its leading position in the global market / Aesthetics business reinforced by focused internationalization strategy / Healthy development in non-prescribed products

• 03. June 2011

  IQWiG recognizes the benefits of Memantine

  In its recently published Rapid Report, the Institute for Quality and Efficiency in Healthcare (IQWiG) acknowledges that the anti-dementive Memantine (Axura®) is beneficial in the area of cognitive functional capacity and that there are indications of a benefit in the everyday capabilities of patients suffering from Alzheimer’s dementia.

• 03. June 2011

  Raymond C. Stevens serves as the 21st Friedrich Merz Foundation Visiting Professor

  Professor Raymond C. Stevens from the Scripps Research Institute in La Jolla (USA) was appointed as this year’s Friedrich Merz Foundation’s Visiting Professor for Pharmacology and Human Medicine at the Goethe University in Frankfurt.